

Marc Laine

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3093679/marc-laine-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

1,761
citations

16
h-index

41
g-index

86
ext. papers

2,084
ext. citations

5.9
avg, IF

3.89
L-index

#	Paper	IF	Citations
78	Haemodynamic support during high-risk percutaneous coronary intervention.. <i>Archives of Cardiovascular Diseases</i> , 2022 , 115, 109-109	2.7	
77	-HH Gene Variants Encoding the Fc Gamma Receptor for the C-Reactive Protein Are Associated with Enhanced Monocyte CD32 Expression and Cardiovascular EventsTRecurrence after Primary Acute Coronary Syndrome.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
76	On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 923-930	7	1
75	Antithrombotic strategies in elderly patients with acute coronary syndrome. <i>Archives of Cardiovascular Diseases</i> , 2021 , 114, 232-245	2.7	1
74	Acute Coronary Syndrome in the Era of SARS-CoV-2 Infection: A Registry of the French Group of Acute Cardiac Care. <i>CJC Open</i> , 2021 , 3, 311-317	2	9
73	Impella CP Implantation during Cardiopulmonary Resuscitation for Cardiac Arrest: A Multicenter Experience. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
72	TicagRelor Or Clopidogrel in severe or terminal chronic kidney patients Undergoing PERcutaneous coronary intervention for acute coronary syndrome: The TROUPER trial. <i>American Heart Journal</i> , 2020 , 225, 19-26	4.9	9
71	High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome. <i>Atherosclerosis</i> , 2020 , 293, 86-91	3.1	0
70	Reply: The Challenge of Researching Pre-Treatment Omission With Invasive Strategy Timing in NSTEMACS. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 1726-1727	5	
69	Hemodynamic Profiles of Cardiogenic Shock Depending on Their Etiology. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
68	Anakinra for severe forms of COVID-19. <i>Lancet Rheumatology, The</i> , 2020 , 2, e586	14.2	1
67	Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis 2020 , 8,		14
66	Doppler echocardiography for assessment of systemic vascular resistances in cardiogenic shock patients. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 102-107	4.3	3
65	Optimal Timing of Intervention in NSTEMACS Without Pre-Treatment: The EARLY Randomized Trial. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 907-917	5	15
64	Letter by Delmas et al Regarding Article, "Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock: Matched-Pair IABP-SHOCK II Trial 30-Day Mortality Analysis". <i>Circulation</i> , 2019 , 140, e555-e556	16.7	
63	Response to the letter to the editor: anticoagulant activity of bivalirudin. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1415	4	
62	Letter by Laine et al Regarding Article, "Antithrombotic Agents: New Directions in Antithrombotic Therapy". <i>Circulation Research</i> , 2019 , 124, e117-e118	15.7	

61	Is there still a role for the intra-aortic balloon pump in the management of cardiogenic shock following acute coronary syndrome?. <i>Archives of Cardiovascular Diseases</i> , 2019 , 112, 792-798	2.7	1
60	Letter by Bonello et al Regarding Article, "Early Versus Standard Care Invasive Examination and Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: VERDICT Randomized Controlled Trial". <i>Circulation</i> , 2019 , 139, e959-e960	16.7	
59	Dynamic iron status after acute heart failure. <i>Archives of Cardiovascular Diseases</i> , 2019 , 112, 410-419	2.7	5
58	Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2188-2195	15.4	3
57	Etiology and Prognosis of Cardiogenic Shock in a Secondary Center without Surgical Back-Up. <i>Cardiology Research and Practice</i> , 2019 , 2019, 3869603	1.9	1
56	Device-Related Thrombus After Left Atrial Appendage Occlusion With the Amulet Device. <i>Heart Lung and Circulation</i> , 2019 , 28, 1683-1688	1.8	3
55	Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 295-304	4	6
54	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. <i>Platelets</i> , 2019 , 30, 105-111	3.6	1
53	Impact of the time-to-treatment concept on the outcome of acute heart failure: A pilot study. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 270-275	2.7	2
52	Specific Pharmacological Profile of A Adenosine Receptor Predicts Reduced Fractional Flow Reserve in Patients With Suspected Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	11
51	Uric acid levels are associated with endothelial dysfunction and severity of coronary atherosclerosis during a first episode of acute coronary syndrome. <i>Purinergic Signalling</i> , 2018 , 14, 191-199	3.8	24
50	Early versus delayed invasive strategy for intermediate- and high-risk acute coronary syndromes managed without P2Y receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial. <i>Clinical Cardiology</i> , 2018 , 41, 5-12	3.3	5
49	Dabigatran versus vitamin k antagonist: an observational across-cohort comparison in acute coronary syndrome patients with atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2018 , 16, 465-473	15.4	6
48	Great expectations. <i>Lancet, The</i> , 2018 , 391, 306	4.0	
47	Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach. <i>Archives of Cardiovascular Diseases</i> , 2018 , 111, 109-118	2.7	13
46	Ventricular Arrhythmia Occurrence and Compliance in Patients Treated With the Wearable Cardioverter Defibrillator Following Percutaneous Coronary Intervention. <i>Heart Lung and Circulation</i> , 2018 , 27, 984-988	1.8	4
45	Mechanical Support in Cardiogenic Shock Complicating Acute Coronary Syndrome: Ready for Prime Time?. <i>Current Vascular Pharmacology</i> , 2018 , 16, 418-426	3.3	3
44	Adenosine Plasma Level and A2A Receptor Expression in Patients With Cardiogenic Shock. <i>Critical Care Medicine</i> , 2018 , 46, e874-e880	1.4	6

43	Meta-Analysis of Potent P2Y12-ADP Receptor Antagonist Therapy Compared to Clopidogrel Therapy in Acute Coronary Syndrome Patients with Chronic Kidney Disease. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 1839-1846	7	11
42	Platelet Reactivity: Journey to the End of the Night. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 114	15.1	2
41	Parameters of complete blood count do not predict on-treatment platelet reactivity in acute coronary syndrome patients. <i>Thrombosis Research</i> , 2017 , 152, 38-40	8.2	
40	Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 1522-1523	15.4	1
39	Controlled sedation with midazolam and analgesia with nalbuphine to alleviate pain in patients undergoing subcutaneous implantable cardioverter defibrillator implantation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017 , 49, 191-196	2.4	11
38	Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey. <i>International Journal of Cardiology</i> , 2017 , 241, 387-392	3.2	21
37	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017 , 136, 2085-2087	16.7	230
36	Prehospital and in-hospital course of care for patients with acute heart failure: Features and impact on prognosis in "real life". <i>Archives of Cardiovascular Diseases</i> , 2017 , 110, 72-81	2.7	4
35	Research and Therapeutic Nihilisms in Chronic Kidney Disease. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2343-2344	5	2
34	Wearable cardioverter defibrillator: Bridge or alternative to implantation?. <i>World Journal of Cardiology</i> , 2017 , 9, 531-538	2.1	9
33	Timing of Coronary Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes: An Updated Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 2267-2276	5	44
32	Management and research in cancer treatment-related cardiovascular toxicity: Challenges and perspectives. <i>International Journal of Cardiology</i> , 2016 , 224, 366-375	3.2	19
31	Personalized Antiplatelet Therapy: The Odyssey Continues. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 105-106	5	1
30	P2Y12-ADP receptor antagonists: Days of future and past. <i>World Journal of Cardiology</i> , 2016 , 8, 327-32	2.1	14
29	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2016 , 220, 496-500	3.2	10
28	Pleiotropic effects of ticagrelor: Myth or reality?. <i>Archives of Cardiovascular Diseases</i> , 2016 , 109, 445-8	2.7	5
27	Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2016 , 216, 190-3	3.2	6
26	In dubious battle: bleeding versus ischemic events. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 42, 294-5	5.1	

25	Clopidogrel Response Variability: Etiology and Clinical Relevance. <i>Current Cardiovascular Risk Reports</i> , 2015 , 9, 1	0.9	0
24	Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study. <i>International Journal of Cardiology</i> , 2015 , 187, 502-7	3.2	29
23	Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2015 , 116, 339-43	3	24
22	Simultaneous pulmonary vein cryoablation and cavotricuspid isthmus radiofrequency ablation in patients with combined atrial fibrillation and typical atrial flutter. <i>Journal of Electrocardiology</i> , 2015 , 48, 729-33	1.4	
21	Low basal expression of A2A adenosine receptors and increase in adenosine plasma concentration are associated with positive exercise stress testing. <i>International Journal of Cardiology</i> , 2015 , 180, 15-7	3.2	13
20	COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctiON patients: The COMPASSION study. <i>Platelets</i> , 2015 , 26, 570-2	3.6	12
19	Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 702-7	7	17
18	Antiplatelet properties of oral anticoagulants. <i>International Journal of Cardiology</i> , 2015 , 181, 413-4	3.2	5
17	Vasodilator-Stimulated Phosphoprotein (VASP) Assay 2014 , 58-64		
16	Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients. <i>International Journal of Cardiology</i> , 2014 , 173, 120-1	3.2	32
15	Résistance aux antiagrégants plaquettaires : où en est-on en pratique ?. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2014 , 2014, 34-37	0	
14	Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 273-8	7	53
13	Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 872-7	15.1	211
12	Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2013 , 132, e15-8	8.2	23
11	Clinical impact of genetically determined platelet reactivity. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 398-403	3.3	5
10	Assessing post-treatment platelet reactivity: a focus on patient selection and setting. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1557-66	2.5	1
9	Improved biological efficacy of prasugrel one month after an acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013 , 167, 2329-30	3.2	
8	Biological efficacy and clinical safety of a second 600 mg loading dose of clopidogrel in elderly patients with high on-treatment platelet reactivity: a pilot study. <i>International Journal of Cardiology</i> , 2013 , 165, 200-1	3.2	1

7	The safety of cardiac resynchronization therapy pacemaker implantation in octogenarians: a monocentric experience. <i>International Journal of Cardiology</i> , 2013 , 168, 2969-70	3.2	18
6	A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity. <i>International Journal of Cardiology</i> , 2013 , 168, 4244-8	3.2	12
5	Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1999-2005	15.4	102
4	Ventricular allorhythmia during infarct-related ventricular tachycardia. <i>Journal of Electrocardiology</i> , 2012 , 45, 394-397	1.4	
3	Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 101-6	7	22
2	Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. <i>New England Journal of Medicine</i> , 2012 , 367, 1297-309	59.2	631
1	Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5392-401	3.3	0